Our service standards

All our programs and projects are developed in close collaboration with our clients and partners to cover their specific needs. We perform our services with integrity and high ethical, compliance and quality standards. 

Each program is carefully reviewed from legal and compliance perspective and, where appropriate, submitted for regulatory approval. Programs are compliant with all applicable laws and regulations and strictly adhere to all specific requirements of the healthcare and pharmaceutical industries, whether they relate to pharmacovigilance, data protection or rules governing the promotion of medicinal products in particular countries.

About us

We are a team of experts in the rare disease area with long-term experience in different management roles in pharmaceutical industry, patient advocacy and patient support programs in Central Europe. 

Our team also includes experienced care coordinators, educational and mobile nurses. We work closely with HCPs and treating centres across the region (esp., in cardiology, neurology, immunology, hematolgy, internal medicine) to bring innovative treatment and care to the rare disease community.

We have in-depth knowledge of developing market entry strategies in Central Europe, identifying eligible patients for innovative therapies, and implementing specialized patient programs to improve patient adherence, outcomes, and quality of life. In each country we work closely with HTA agencies, lawyers, wholesalers, health funds and patient advocacy groups. We put patients first by bringing innovative solutions to care.

Monika Němcová, MD

• LinkedIn

Founder

Monika is an experienced leader with 25 years of successful track record in the biopharmaceutical industry and rare diseases. She established and developed two fully operational Shire subsidiaries (Czech Republic, Slovakia) as Executive Director and built from scratch Alnylam Pharmaceuticals’ direct presence in Central Europe (Czech Republic, Slovakia, Hungary, Baltics, and Poland) as the Director of the Central European Cluster. During her career in the biopharmaceutical industry, she launched and obtained reimbursement for numerous orphan and highly innovative drugs in the Central Europe region. She developed and launched genetic diagnostic screening programs for rare diseases (hATTR, AHP, PH1, Fabry disease) which were accepted and recognized by national medical societies and resulted in a significant increase in the number of diagnosed patients. As the Head of the Palliative and Complex Care Project of Rare Diseases Czech Republic (Czech Rare Disease Patients Alliance), she prepared a strategy for complex and supportive care to be implemented in the national network of expert centres.